Prof. Dr. Claudia Scholl
Phone: +49 6221 421636

To Find and Elucidate...


Druggable Vulnerabilities in Cancer Cells.

Applied Functional Genomics

  • Uras IZ, Walter GJ, Scheicher R, Bellutti F, Prchal-Murphy M, Tigan AS, Valent P, Heidel FH, Kubicek S, Scholl C, Fröhling S, Sexl V. Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6. Blood 127:2890-902, 2016

  • Stolze B, Reinhart S, Bulllinger L, Fröhling S, Scholl C. Comparative analysis of KRAS codon 12, 13, 18, 61, and 117 mutations using human MCF10A isogenic cell lines. Sci Rep 5:8535, 2015.

  • Azoitei N, Diepold K, Brunner C, Rouhi A, Genze F, Becher A, Kestler H, van Lint J, Chiosis G, Koren J 3rd, Fröhling S, Scholl C, Seufferlein T. HSP90 supports tumor growth and angiogenesis through PRKD2 protein stabilization. Cancer Res 74:7125-7136, 2014.

  • Placke T, Faber K, Nonami A, Putwain SL, Salih HR, Heidel FH, Krämer A, Root DE, Barbie DA, Krivtsov AV, Armstrong SA, Hahn WC, Huntly BJ, Sykes SM, Milsom MD, Scholl C,* Fröhling S.* Requirement for CDK6 in MLL-rearranged acute myeloid leukemia. Blood 124:13-23, 2014. *Equal contribution.

  • Faber K, Bullinger L, Ragu C, Garding A, Mertens D, Miller C, Martin D, Walcher D, Döhner K, Döhner H, Claus R, Plass C, Sykes SM, Lane SW, Scholl C,* Fröhling S.* CDX2-driven leukemogenesis involves KLF4 repression and deregulated PPARγ signaling. J Clin Invest 123:299-314, 2013. *Equal contribution.

  • Azoitei N, Hoffmann CM, Ellegast JM, Ball CR, Obermayer K, Gößele U, Koch B, Faber K, Genze F, Schrader M, Kestler HA, Döhner H, Chiosis G, Glimm H, Fröhling S,* Scholl C.* Targeting of KRAS mutant tumors by HSP90 inhibitors involves degradation of STK33. J Exp Med 209:697-711, 2012. *Equal contribution.

  • Sykes SM, Lane SW, Bullinger L, Kalaitzidis D, Yusuf R, Saez B, Ferraro F, Mercier F, Singh H, Brumme KM, Acharya SA, Scholl C, Tothova Z, Attar E, Fröhling S, DePinho RA, Gilliland DG, Armstrong SA, Scadden DT. AKT/FOXO signaling enforces reversible differentiation blockade in myeloid leukemias. Cell 146:697-708, 2011.

  • Scholl C,* Fröhling S,* Dunn IF, Schinzel AC, Barbie DA, Kim SY, Silver SJ, Tamayo P, Wadlow RC, Ramaswamy S, Döhner K, Bullinger L, Sandy P, Boehm JS, Root DE, Jacks T, Hahn WC, Gilliland DG. Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell 137:821-834, 2009. *Equal contribution.

Members of the Scholl, Fröhling, and Gröschel Groups (November 2015)

Ph.D. and postdoc opportunities

If you are interested in joining our research team, please send an email to the group leader including full CV, statement of interest, certificates and references.


Administrative Assistant

Tara Buschle
Administrative Assistant
Phone: +49 6221 42 1637

Scientific Coordinator

Julia Krüwel-Bode, Ph.D.
Scientific Coordinator
Phone: +49 6221 42 1649

Postdoctoral Fellows

Matea Hajnic, Ph.D.
Computational Biologist
Phone: +49 6221 42 3308 or 1649

Ranadip Mandal, Ph.D.
Postdoctoral Fellow
Phone: +49 6221 42 16477

Leila Martins, Ph.D.
Postdoctoral Fellow
Phone: +49 6221 42 3245

PhD Students

Raffaela Bung, M.Sc.
Ph.D. Student
Phone: +49 6221 42 3245

David Feuersinger, M.Sc.
Ph.D. Student
Phone: +49 6221 42 1647

Research Technicians

Jana Kress
Research Technician
Phone: +49 6221 42-1635

Stefanie Reinhart
Research Technician
Phone: +49 6221 42 1635

Dorothee Terhardt
Research Technician
Phone: +49 6221 42 1635

Students, Trainees

Gregor Grill Dr. med. candidate
Gelsomina Kaufhold (Student Assistant)
Alexandra Teslenko (Student Assistant)
Jesko Wagner (Bachelor Student)